Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also developing newer medicines that will improve its financial results. 10 stocks we ...

Is REGN a good stock to buy? We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Ocular Capital’s Substack.

Shares of Regeneron Pharmaceuticals Inc. REGN slid 3.62% to $746.61 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 1.52% ...

Shares of Regeneron Pharmaceuticals Inc. REGN shed 2.87% to $764.93 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.56% to ...

Wondering if Regeneron Pharmaceuticals at around US$764.93 a share still offers value, or if most of the upside is already priced in? This article is designed to help you frame that question clearly.

Regeneron Pharmaceuticals is a leading biotech focused on gene editing. While the S&P 500 has dipped lower in November, Regeneron stock has climbed steadily higher. Despite its recent rise, Regeneron ...

Regeneron's main growth driver should perform well through the end of the decade. The biotech should launch newer medicines in the coming years. Healthcare stocks have underperformed broader equities ...

Sales of Regeneron Pharmaceuticals' Eylea have declined over the past few quarters due to competition. However, the company launched a new formulation of the medicine that just earned another label ...